Nektar Therapeutics Q3 EPS $(0.56) Beats $(0.73) Estimate, Sales $29.218M Beat $26.4M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.73) by 23.29 percent. This is unchanged from the same period last year. The company

Benzinga · 11/06/2019 22:10

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.73) by 23.29 percent. This is unchanged from the same period last year. The company reported quarterly sales of $29.218 million which beat the analyst consensus estimate of $26.4 million by 10.67 percent. This is a 5.24 percent increase over sales of $27.762 million the same period last year.